It was notable that IL12B, LIF and S100A12 emerged as potential therapeutic targets for T1D with renal complications, and that FGF19, FGF23, CCL7, TNFSF14 and IL-13 also deserved attention for T2D with renal complications. Here, FGF23 is linked to type 2 diabetes mellitus.